Patient-derived microglia models show differences between genetic and sporadic FTD
Original source
C9orf72-associated and sporadic FTD patient iPSC-microglia show differences in phagocytosis and gene expression. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human
Population inferred from the title and abstract by Compass.
Related topics
Researchers found differences in phagocytosis and gene activity between laboratory-grown microglia made from people with C9orf72-associated behavioural-variant frontotemporal dementia (bvFTD) and those from people with sporadic bvFTD. The C9orf72 models also showed repeat-associated RNA foci, dipeptide repeat proteins, and changes in pathways involved in cellular recycling.
Why this matters
The findings point to biological differences between genetic and sporadic forms of bvFTD in patient-derived cell models. Because this was a laboratory study of induced pluripotent stem cell-derived microglia, it does not yet change treatment for people with ALS, FTD, or bvFTD.
Limitations and context
This was a primary research study using induced pluripotent stem cell-derived microglia, not people’s brains or a clinical treatment study. The source does not provide the sample size or clinical outcomes, and the findings need confirmation and testing in other models and in people.